Above discussed aspects, considerations and technical possibilities, as well as methodological requirements, guidelines and clinical applications of proton spectroscopy strengthens our belief in the power of this method used in neurooncological diagnosis.
WaleckiJGriebPChojnackaE: In vivo 1HMRS. in intracranial tumors. Polish Journal of Radiology63: 3–225, 1998.
2.
PieniążekPSokółMPrzeorekC: Spektroskopia protonowa magnetycznego rezonansu jądrowego - aspekty metodologiczne o ograniczenia w badaniach mózgu. Rez Magn Med6: 1–11, 1998.
3.
GajewiczW: The use of proton MRS in the differential diagnosis of brain tumors and tumor — like processes. Med Sci Monit9: 97–105, 2003.
4.
PeelingJSutherlandG: High resolution 1H NMR spectroscopy studies of extracts of human celebral neoplasms. Magn Reson Med24: 123, 1992.
5.
NunnallyRLBottomleyPA: Assessment of pharmacological treatment of myocardial infraction by phosphorus 31 NMR with surphace coils. Sience211: 177, 1981.
6.
KellerU: Phosphocreatine content and intracellular pH of calf muscle measured by phosphorus NMR spectroscopy in occlusive arterial disease of the legs. Eur J Clin Invest15: 382, 1985.
7.
HubeshB: P-31 MR spectroscopy of normal human brain tumors. Radiology174: 401, 1990.
8.
van Wassennaer-van HallHNvan der GrondJ: 31P magnetic resonance spectroscopy of the liver: correlation with standaried serum, clinical and histological changes in diffuse liver disease. Hepatology21: 443, 1999.
9.
KloseUBultmannEJiruF: CSI-Measurements of the Human Brain at 3T. Magnetom Flash2: 46, 2005.
10.
in 't ZandtH.van Der GraafM.HeerschapA.: Common processing of in vivo MR spectra, NMR, Biomed14: 224–232, 2001.
11.
BottomleyPA: The trouble with spectroscopy papers. Radiology 991;181: 344–150.
12.
PoulletJSimaDMSimonettiAW: An automated quantitation of short echo time MRS spectra in an open source software environment: AQSES, NMR Biomed20: 493–504, 2007.
13.
RatineyHSdikaMCoenradieY: Time-domain semi-parametric estimation based on a metabolite basis set, NMR Biomed18; 1–13, 2005.
14.
ElsterCSchubertFLinkA: Quantitative magnetic resonance spectroscopy: Semi-parametric modeling and determination of uncertainties, Magn Reson Med53: 1288–96, 2005.
ManssonS: 13C imaging - a new diagnostic platform. EurRadiol16: 57–67, 2006.
19.
HollingworthW: A Systematic Literature Review of MRS for the Characterization of Brain Tumors. Am J Neuroradiol27: 1404–1410, 2006.
20.
YangD: Cerebral glioma: prospective comparison of multivoxel 2D chemical - shift imaging proton MRS, echoplanar perfusion and diffusion - weighted MRI. Neuroradiology44: 656–666, 2002.
21.
MajosC: Proton magnetic resonance spectroscopy (1H MRS) of human brain tumors: assessment of differences between tumor types and its applicability in brain tumor categorization. Eur Radiol13: 582–591, 2003.
22.
WaleckiJ: Role of short TE 1H-MRS in monitoring of post-operation irradiated patients. Eur J Radiol30: 154–161, 1999.
23.
BurtscherI: 1H MRS and preoperative diagnostic accuracy: an evaluation of pts with intracranial mass lesions who underwent stereotactic biopsy. Phd Thesis, Lund Univ. Sweden1999.
24.
BhujwallaZM: Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy. Int J. Radiat. Oncol. Biol. Phys. 36: 635–639, 1996.
25.
TarnawskiR: 1HMRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. Int J Radiat Oncol boil Phys: 1271–1276, 2002.
